Tag:

Avid Radiopharmaceuticals

Latest Headlines

Latest Headlines

FDA rejects Lilly, Avid Alzheimer's test dye

Earlier this month, Eli Lilly ($LLY) CEO John Lechleiter (photo) predicted the FDA would approve Amyvid, a new molecular imaging agent that could revolutionize Alzheimer's diagnosis by detecting the

Lilly ($LLY) snags Avid Radiopharmaceuticals in $800M buyout deal

Frustrated by a series of nasty setbacks in the clinic, pharma giant Eli Lilly ($LLY) is writing a $300 million check to acquire Avid Radiopharmaceuticals, a diagnostics company that has garnered

New studies will test preventive Alzheimer's therapies

The Washington Post examines several ambitious new studies designed to accurately identify the early onset of Alzheimer's and use biomarkers to track the effectiveness of new therapies to prevent the

Brain dye can spot Alzheimer's

A study has found that researchers can detect Alzheimer's disease with a brain scan using radioactive dye called AV-45 or florbetapir, which was developed by Philadelphia-based Avid

Eli Lilly bets big on late-stage Alzheimer's drugs

Alzheimer's has long been one of the most difficult and confusing targets in drug development. But lured by the prospect of mega-blockbuster revenue for any new drug that alleviates key symptoms of

Avid's radiotracer proves effective in diagnosing Alzheimer's

While Alzheimer's has long represented an enormous potential market for drug developers, the field has been plagued for decades by some vexing scientific challenges. There often seems to be more

Avid, Sagent raise new millions in venture funds

A pair of U.S. biotech companies has collectively raised more than $64 million in increasingly scarce venture funds. Philadelphia-based Avid Radiopharmaceuticals- which makes molecular imaging